Group II metabotropic glutamate receptors as targets for novel antipsychotic drugs
Schizophrenia is a chronic psychiatric disorder which substantially impairs patients’ quality of life. Despite the extensive research in this field, the pathophysiology and aetiology of schizophrenia remain unknown. Different neurotransmitter systems and functional networks have been found to be aff...
Main Authors: | Carolina eMuguruza, Javier eMeana, Luis F Callado |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2016-05-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00130/full |
Similar Items
-
Group I Metabotropic Glutamate Receptors and Interacting Partners: An Update
by: Li-Min Mao, et al.
Published: (2022-01-01) -
Inhibition of the Interaction Between Group I Metabotropic Glutamate Receptors and PDZ-Domain Proteins Prevents Hippocampal Long-Term Depression, but Not Long-Term Potentiation
by: Sergey Neyman, et al.
Published: (2019-04-01) -
Phosphorylation and regulation of group II metabotropic glutamate receptors (mGlu2/3) in neurons
by: Li-Min Mao, et al.
Published: (2022-11-01) -
The Physio-Pathological Role of Group I Metabotropic Glutamate Receptors Expressed by Microglia in Health and Disease with a Focus on Amyotrophic Lateral Sclerosis
by: Matilde Balbi, et al.
Published: (2023-03-01) -
Glutamate Metabotropic Receptor Type 3 (mGlu3) Localization in the Rat Prelimbic Medial Prefrontal Cortex
by: Elizabeth Woo, et al.
Published: (2022-04-01)